옵션 체인은 다양한 행사가격과 만기일에 대한 Longeveron의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Longeveron에 대한 시장 심리를 평가합니다..

Longeveron (NASDAQ:LGVN) 주식, 옵션 체인

LONGEVERON INC-A

Longeveron

Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.

Digital,Marketing,Data,Analytic,Technology,,Businessman,Using,Laptop,Computer,To

Exclusives

Tech

Trading Ideas

ETFs

AAPL

AMZN

CRWD

KOSS

LGVN

MIRA

MSFT

NUZE

NVDA

PLTR

SERV

SMCI

SOBR

TSLA

ZAPP

각 거래일에는 트레이더들이 전체 시장과 개별 종목들에 대한 최신 뉴스를 볼 수 있는 소스의 하나인 Benzinga Pro에 수백 개의 헤드라인과 보도 자료가 제공된다. 2024년 7월 한 달 동안 Benzinga Pro에서 가장 많이 검색된 주식을 살펴보겠다. 현재 가격과 연간 실적은 8월 1일을 기준으로 하며 배당금은 포함되지 않는다. 4월 검색결과는 추적되지 않았다.

단독: 7월 벤징가 프로에서 가장 많이 검색된 상위 20개 종목 - 테슬라, 엔비디아, CRWD 순위는?

ASNS

AVGO

DELL

FFIE

MLGO

RIVN

각 거래일에는 트레이더들이 전체 시장과 개별 종목에 대한 최신 뉴스를 볼 수 있는 소스인 Benzinga Pro에 수백 개의 헤드라인과 보도 자료가 제공된다. 6월 한 달 동안 Benzinga Pro에서 가장 많이 검색된 주식을 살펴보겠다. 현재 가격과 연간 성과는 6월 30일 기준이며 배당금은 포함되어 있지 않다. 4월 검색결과는 추적되지 않았다.

단독: 6월 벤징가 프로에서 가장 많이 검색된 상위 10종목 - 엔비디아, 애플, 테슬라는 어디에?

Longeveron Inc

Longeveron (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGVN#NASDAQ">LGVN</a>) reported quarterly losses of $(0.34) per share which missed the analyst consensus estimate of $(0.30) by 13.33 percent. This is a 78.88 percent increase over losses of $(1.61) per share from the same period last year. The company reported quarterly sales of $381.00 thousand which missed the analyst consensus estimate of $608.25 thousand by 37.36 percent. This is a 30.47 percent decrease over sales of $548.00 thousand the same period last year.

Earnings

Earnings Misses

News

Longeveron Q1 EPS $(0.34) Misses $(0.30) Estimate, Sales $381.00K Miss $608.25K Estimate

AAOI

ABCL

ABEV

ACIC

ACIW

ACMR

ACTG

AFRM

AKAM

AKBA

ALGM

ALIT

ALRM

ALXO

Amplify YieldShares Oil Hedged MLP Income ETF

AMLX

AMPX

AMTX

APPN

APYX

AQMS

ARGX

ARHS

ARKO

ARLO

ASPN

ASTH

Adtalem Global Education Inc. Common Stock

ATGE

ATHM

ATUS

AUTL

AVAH

AVPT

AXGN

BAER

BBDC

BIGC

BILL

BIRD

BlackSky Technology Inc. Class A Common Stock

BKSY

BLFS

BLND

CARG

CARS

CBLL

CBUS

CCEC

CCOI

CCRD

CDTX

CION

CLAR

CLFD

CLNE

CLSK

CMPS

CMRE

CODX

COIN

COLD

COLL

COMP

CRNX

CRON

CROX

CRVS

CTEV

CTKB

CTLP

CVRX

DAVE

DCGO

DCTH

DIOD

DKNG

Earnings Scheduled For May 8, 2025

Dear Fellow Shareholders,
Twenty twenty-four was a year of execution for Longeveron. We made significant progress advancing Longeveron's founding mission - developing cutting-edge cellular therapy research to impact patients' lives for the better by addressing unmet medical needs. We have come a long way pursuing that mission and now have clarity on the pathway to our first potential Biological License Application (BLA) submission.
Today, I am excited to update you on our overall strategy, progress, and key priorities and goals for 2025.
Strategic Overview and 2024 Progress: Over the past decade, stem cell therapy has seen remarkable strides, transforming from a promising field into one delivering tangible clinical outcomes. We've seen the solidification of cell therapy's role in regenerative medicine and its potential to treat a wide range of conditions, signaling an exciting future for both scientific innovation and patient care.
Longeveron has been at the forefront of this evolution in medicine. Our lead investigational product is laromestrocel (Lomecel-B&#x2122;), a stem cell therapy derived from culture-expanded mesenchymal stem cells (MSCs) that are sourced from bone marrow of young healthy adult donors. The number of functional MSCs in the body declines as we age, which has driven interest in their use for aging-related conditions. Their unique properties — including the ability to reduce inflammation, promote tissue repair and regeneration, modulate immune responses, and improve vascularization — also support their application in some rare cardiovascular diseases/conditions with high unmet medical need. We believe that by using the same cells that promote tissue repair, organ maintenance, and immune system function, we can develop safe and effective therapies for some of the most difficult diseases and conditions.
A decade ago, our stem cell therapy vision was an academic idea. Today, laromestrocel represents a pipeline in a product opportunity that has delivered positive results from multiple clinical trials: Phase 1 &amp; 2 in Alzheimer's disease, Phase 1 &amp; 2 in Aging-related Frailty, Phase 1 in Hypoplastic Left Heart Syndrome (HLHS), a rare pediatric disease. We are currently conducting a pivotal Phase 2b clinical trial for HLHS. Our development programs for these 3 initial indications address market opportunities of what we estimate to be approximately ~$5+ billion, ~$4+ billion and up to ~$1 billion, respectively. Earlier this year, the World Health Organization's International Nonproprietary Names (INN) Expert Committee approved "laromestrocel" as the non-proprietary name for Lomecel-B&#x2122; — a key milestone in the development and future commercialization of our stem cell therapy.
As we did this past year, in 2025, we will continue focusing our efforts on two of our most promising programs: HLHS and Alzheimer's disease.
Hypoplastic Left Heart Syndrome (HLHS):
HLHS is a rare pediatric disease in which the left ventricle (one of the pumping chambers of the heart) is either severely underdeveloped or missing. Because the left ventricle is the chamber that normally pumps blood to the body, infants born with this condition have a profound reduction in blood flow and thus cannot get the normal supply of oxygen to their organs. In order for the children to survive, they must undergo a complicated, three-stage heart reconstruction surgery over the course of the first 5 years of their lives. Despite this surgical reconstruction, only 50% of the affected children survive to age 15 without heart transplantation.
Our program is designed to boost/improve the heart function in these children with the goal of potentially enhancing their survival. In our Phase I clinical trial (ELPIS I) evaluating laromestrocel in 4-month-old infants with HLHS, we observed 100% transplant-free survival up to five years following treatment. This contrasts with an approximately 20% mortality rate observed in historical control data. Five-year post-treatment long-term survival data from the ELPIS I Phase 1 clinical trial was presented at the Congenital Heart Surgeons' Society (CHSS) 51st Annual Meeting in October 2024.
We are currently nearing completion of enrollment for our Phase 2b study, ELPIS II, which is evaluating laromestrocel as a potential adjunct treatment to the standard of care for HLHS. ELPIS II has achieved nearly 95% enrollment, and we expect to complete enrollment in the second quarter of this year.
In September 2024, we completed a Type C meeting with the U.S. FDA regarding our HLHS development program and the pathway toward a potential BLA submission. We reached foundational alignment on the primary endpoint and secondary endpoints for the ELPIS II trial. The FDA confirmed that, contingent on positive results, ELPIS II may be considered a pivotal trial and potentially acceptable for BLA submission seeking full traditional approval. With this regulatory clarity, we are now focused on BLA preparedness and enabling activities for the HLHS program. Notably, because this program has received Rare Pediatric Disease Designation, we may be eligible to receive a Priority Review Voucher (PRV) if our BLA is approved. We may use the PRV internally or sell to a third party. Historically, PRVs have commanded values exceeding $100 million.
Alzheimer's Disease:
The laromestrocel Alzheimer's disease (AD) program continues to garner important recognition and support. In 2024, data from the CLEAR MIND Phase 2a clinical trial evaluating laromestrocel in mild Alzheimer's disease were presented as a featured research oral presentation at the 2024 Alzheimer's Association International Conference held at the end of July and as a late breaking poster presentation at the 17th edition of the Clinical Trials on Alzheimer's Disease Conference (CTAD24) in October. We are very excited about the trial's positive results. The trial met its primary objective of demonstrating safety, with laromestrocel being well-tolerated. In addition, we observed encouraging trends suggesting a potential slowing or prevention of disease progression in patients treated with laromestrocel compared to placebo.
This program has received Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations, providing us with the opportunity for enhanced and frequent communication with the FDA to facilitate the development and review process. In March of this year, results from the trial were <a href="https://www.globenewswire.com/Tracker?data=q5z76BEDJ6-_BNlI7zxiW7bj7HH_JA6z2l_-sTbO61K_qKYtMQAMaF9FDMVXrEj3T_9nYmWCk-Lq0zdwrX4bx2qd5ntW3sf1N8Ytp1j1BkoTux4GUbqWzdOydRL9flts">published</a> in Nature Medicine.
Also in March of this year, we held a Type B meeting with the FDA to discuss the regulatory pathway for a potential BLA for laromestrocel in mild Alzheimer's disease. We reached foundational alignment on the overall study design for a proposed single, pivotal, seamless adaptive Phase 2/3 clinical trial. To support an accelerated path to potential approval, the FDA agreed to consider a BLA submission based on positive interim results from this planned single study.
With this regulatory clarity in hand, we are focused on seeking partnership opportunities and/or non-dilutive funding for the Alzheimer's disease program.
Our Core Business Objectives: Our strategic plan is built on the strength of the science underlying our stem cell therapy laromestrocel. For 2025, we are focused on four key objectives:
<ol>
<li>Advance HLHS Program as the Main Near-Term Value Driver:
<ul>
<li>Pivotal Phase 2 clinical trial (ELPIS II) is nearing enrollment completion.</li>
<li>Regulatory pathway clarified with U.S. FDA.</li>
<li>Potential to initiate rolling BLA submission in 2026.</li>
<li>Potential to receive a Rare Pediatric Disease priority review voucher associated with HLHS upon BLA approval which could have significant monetary value and further enhance our product's value proposition upon approval.</li>
</ul>
</li>
<li>HLHS BLA and Commercialization Readiness:
<ul>
<li>Successful meeting with FDA confirmed ELPIS II could be pivotal.</li>
<li>2025 will see significant focus on organizational readiness for potential BLA filing for HLHS in 2026. Our goal is to accomplish BLA readiness this year ahead of data readout to potentially shorten the timeline to BLA submission.</li>
<li>Emphasis on Chemistry, Manufacturing, and Controls (CMC) preparedness.</li>
<li>Hired industry veteran Chief Technology Officer to support BLA preparedness.</li>
<li>We are committed to helping HLHS patients worldwide. In 2025, we intend to take initial steps connecting with non-U.S. regulatory bodies, including EMA (European Union), MHRA (United Kingdom), PMDA (Japan) and HealthCanada.</li>
<li>Recognizing substantial revenue potential from worldwide commercialization, we anticipate capitalizing on recent rare disease pricing trends and the unique aspects of our treatment.</li>
</ul>
</li>
<li>Strategic Collaborations for Alzheimer's Disease:
<ul>
<li>We believe our Alzheimer's disease program holds immense potential. Due to the large size of the affected population, it involves larger-scale studies and commercialization requirements. This scale of development effort necessitates significant investment, prompting our focus on potential strategic partnerships with biotech/pharmaceutical companies and/or non-dilutive funding sources.</li>
<li>We believe the clarity on the pathway to potential BLA submission and the need for only a single pivotal clinical trial enhance the attractiveness and economic benefits of the program to potential partners.</li>
</ul>
</li>
<li>Efficient Resource Management and Capital Allocation:
<ul>
<li>We strive to be prudent stewards of shareholder capital and focus allocating it to the organization's top priorities to effectuate optimal resource utilization and alignment with strategic objectives.</li>
<li>We prudently manage expenses. In 2024, we reduced total operating expenses 13% while continuing to effectively advance our development programs.</li>
</ul>
</li>
</ol>
Financial Position and Capital Strategy: Longeveron is working diligently to effectively advance our development programs while managing expenses and our capital. We will need additional capital to achieve our business strategy and objectives.
We indicated in our recently filed Annual Report on Form 10K that we anticipated our existing cash and cash equivalents would fund our operating expenses and capital expenditure requirements into the fourth quarter of 2025. However, as we also indicated, as a result of our successful Type C meeting with the FDA in August 2024 with respect to the HLHS regulatory pathway, we have started to ramp up BLA enabling activities to prepare for a potential filing with the FDA in 2026 if the current ELPIS II trial is successful. We expect our operating expenses and capital expenditure requirements to accelerate this year as a result of these activities, including CMC (Chemistry, Manufacturing, and Controls) and manufacturing readiness. We intend to seek additional financing and non-dilutive funding options to support these activities, and additional non-dilutive funding and/or strategic partners to support the AD development program. We anticipate that our current cash projections may be impacted by these ramped up activities and any financing transactions we enter into.
2025 Goals and Priorities Our goals for 2025 center on efficient, effective execution of our strategic plan with an emphasis on three primary operational goals:
<ol>
<li>ELPIS II Completion: We anticipate completion of ELPIS II enrollment in the second quarter of 2025. We will then focus on supporting our investigative sites through completion of the 12-month primary endpoint follow-up period and preparation for data collection and analysis at the end of the study.</li>
<li>HLHS BLA Preparedness: We intend to accomplish the majority of BLA readiness in 2025 to support a potentially shortened time frame from clinical trial readout to BLA submission.</li>
<li>Alzheimer's Disease Program Partnering: We plan to leverage the strength of our Phase 2 data and clarity on the clinical pathway to a potential BLA for AD to engage with potential funding/commercialization partners. &nbsp;</li>
</ol>
Outlook Longeveron has made tremendous progress in two important stem cell development programs over the past 12 months, successfully delivering on our strategic plan. We are now approaching multiple potentially transformational milestones over the next 12 months including completion of enrollment in our pivotal Phase 2b clinical trial in HLHS which may establish the timeline for a potential BLA submission for HLHS, and potential partnering for the Alzheimer's disease program. Our team's expertise and industry experience enable the organization to accomplish so much with a small team and few resources. Generating several positive initial results across five clinical trials in three indications, continues to position Longeveron as a leader in stem cell therapy research and, potentially, commercialization of cellular therapeutics.
We believe Longeveron's demonstrated track record of successful clinical execution, strength of data generated to date and the potential size of addressable markets provide for a compelling investment opportunity.
We deeply appreciate the support of our stakeholders and look forward to continued collaboration and progress in the future.
Sincerely, Wa'el Hashad CEO, Longeveron

Longeveron Issues Letter To Shareholders

Offerings

Longeveron Files For Mixed Shelf Of Up To $70M

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Longeveron (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGVN#NASDAQ">LGVN</a>) with a Buy and maintains $10 price target.

Price Target

Reiteration

Analyst Ratings

HC Wainwright & Co. Reiterates Buy on Longeveron, Maintains $10 Price Target

<a href="https://www.globenewswire.com/Tracker?data=CfDdIU-vUWn-uP7WHZnuaEMaCT_kqK23e2B2rnWSgQ5QTVFsFxDKp6KvoNJv4aIe5LwgelnDBkS8uQ2d1vFWv_zrjJe72SQMKwWgyt9sjno=">Longeveron Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGVN#NASDAQ">LGVN</a>), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced the positive outcome of a Type B meeting with the U.S. Food and Drug Administration (FDA), supporting the advancement of <a href="https://www.globenewswire.com/Tracker?data=vYENKpHkG8Q8TKtnRxrYYFtmm_mUPJS_XTwI5jShRSwA5Dr06tUzISpzZEL9NxPouMnJI0KUgXAnhKBQomWSBWMdIFwZsURvx6s39Xd4YDgljvier2cBsVb7vvOcmB2C">laromestrocel (Lomecel-B</a><a href="https://www.globenewswire.com/Tracker?data=H-H0Ucz0WPTEb36hcT-70z9e_WbFg-Z8bsgF9UaKGYDsTdENcA3nzIgYTf8iKQEYwAVwH-nb1iksUeViM8KA1Q==">TM</a>), a proprietary, scalable, allogeneic, investigational cellular therapy, as a potential treatment for <a href="https://www.globenewswire.com/Tracker?data=wZ5v0WKJTKNsAImVqEvVI5wS4Ce0JLoAGRVmvMihw6AXPD-OIwMKUX0v-4Cqp7P6jgGfR-1NN6SepnEXcg1bxn_PeVHqlbgbL8N4JlbAV4Y=">Alzheimer's</a> disease (AD).
The Company and the FDA reached foundational alignment on the overall study design for a proposed single, pivotal, seamless adaptive Phase 2/3 clinical trial, including proposed AD patient population, proposed placebo control, laromestrocel (Lomecel-BTM) dose selection and frequency, trial duration and trial endpoints. To accelerate the pathway to potential approval, the FDA agreed to consider a BLA based on positive interim trial results from the planned single study.

Longeveron Says Co. And FDA Reached Foundational Alignment On Overall Study Design Supporting Laromestrocel In Alzheimer's Disease

<ul>
<li>Phase 2a results demonstrated laromestrocel (Lomecel-B&#x2122;) improved cognitive function, quality of life, and brain volume in the treatment of mild Alzheimer's disease</li>
<li>This encouraging clinical trial data adds to the body of evidence supporting the safety of single and multiple doses of laromestrocel (Lomecel-B&#x2122;) treatment for mild Alzheimer's disease and provides indications of efficacy in combating decline of brain volume and potentially cognitive function</li>
<li>Laromestrocel (Lomecel-B&#x2122;) is, to Company's knowledge, the first cellular therapeutic candidate to receive U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) designation for Alzheimer's disease</li>
</ul>

Biotech

General

Longeveron Publishes Results Of Phase 2a Clinical Trial Evaluating Laromestrocel In Alzheimer's Disease In Nature Medicine

WIIM

Longeveron shares are trading higher after the company provided 2024 clinical updates and financial results.

Longeveron (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGVN#NASDAQ">LGVN</a>) reported quarterly losses of $(2.62) per share which beat the analyst consensus estimate of $(3.53) by 25.78 percent. The company reported quarterly sales of $2.392 million which beat the analyst consensus estimate of $2.143 million by 11.63 percent.

Longeveron FY 2024 GAAP EPS $(2.62) Beats $(3.53) Estimate, Sales $2.392M Beat $2.143M Estimate

<h3>Companies Reporting Before The Bell</h3>
• Frontline (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FRO#NYSE">FRO</a>) is estimated to report quarterly earnings at $0.27 per share on revenue of $282.62 million. 
• Nordic American Tankers (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NAT#NYSE">NAT</a>) is estimated to report quarterly earnings at $0.04 per share on revenue of $53.07 million. 
• Fluent (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLNT#NASDAQ">FLNT</a>) is estimated to report quarterly loss at $0.23 per share on revenue of $68.06 million. 
• Recursion Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>) is expected to report quarterly loss at $0.41 per share on revenue of $18.17 million. 
• Oxford Square Cap (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OXSQ#NASDAQ">OXSQ</a>) is projected to report quarterly earnings at $0.06 per share on revenue of $9.90 million. 
• Integral Ad Science (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IAS#NASDAQ">IAS</a>) is estimated to report quarterly earnings at $0.25 per share on revenue of $148.94 million. 
• PAR Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAR#NYSE">PAR</a>) is estimated to report quarterly loss at $0.08 per share on revenue of $99.26 million. 
• ANI Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIP#NASDAQ">ANIP</a>) is expected to report quarterly earnings at $0.31 per share on revenue of $175.12 million. 
• TeraWulf (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WULF#NASDAQ">WULF</a>) is estimated to report quarterly loss at $0.02 per share on revenue of $37.36 million. 
• Global Partners (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLP#NYSE">GLP</a>) is estimated to report quarterly earnings at $0.90 per share on revenue of $5.80 billion. 
• Rapid Micro Biosystems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPID#NASDAQ">RPID</a>) is expected to report quarterly loss at $0.22 per share on revenue of $7.60 million. 
• FuboTV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FUBO#NYSE">FUBO</a>) is estimated to report quarterly loss at $0.11 per share on revenue of $444.91 million. 
• Butterfly Network (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BFLY#NYSE">BFLY</a>) is expected to report quarterly loss at $0.08 per share on revenue of $21.01 million. 
• Natural Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRP#NYSE">NRP</a>) is projected to report earnings for its fourth quarter. 
• Apellis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>) is expected to report quarterly loss at $0.37 per share on revenue of $191.93 million. 
• Calumet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLMT#NASDAQ">CLMT</a>) is estimated to report quarterly loss at $0.36 per share on revenue of $929.11 million. 
• 1stdibs.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DIBS#NASDAQ">DIBS</a>) is estimated to report quarterly earnings at $0.00 per share on revenue of $22.02 million. 
• LandBridge (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LB#NYSE">LB</a>) is projected to report quarterly earnings at $0.78 per share on revenue of $244.81 million. 
• Fulgent Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLGT#NASDAQ">FLGT</a>) is estimated to report quarterly loss at $0.37 per share on revenue of $75.39 million. 
• Owens &amp; Minor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OMI#NYSE">OMI</a>) is estimated to report quarterly earnings at $0.53 per share on revenue of $2.73 billion. 
• Amneal Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMRX#NASDAQ">AMRX</a>) is projected to report quarterly earnings at $0.15 per share on revenue of $700.83 million. 
• Banco Latinoamericano (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLX#NYSE">BLX</a>) is likely to report quarterly earnings at $0.44 per share on revenue of $251.03 million. 
• Chart Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GTLS#NYSE">GTLS</a>) is expected to report quarterly earnings at $3.23 per share on revenue of $1.18 billion. 
• Alpha Metallurgical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMR#NYSE">AMR</a>) is estimated to report quarterly earnings at $1.12 per share on revenue of $683.10 million. 
• Docebo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCBO#NASDAQ">DCBO</a>) is expected to report quarterly earnings at $0.27 per share on revenue of $56.24 million. 
• Northwest Natural Hldg (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NWN#NYSE">NWN</a>) is expected to report quarterly earnings at $1.49 per share on revenue of $395.05 million. 
<h3>Companies Reporting After The Bell</h3>
• BIT Mining (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BTCM#NYSE">BTCM</a>) is estimated to report earnings for its fourth quarter. 
• Monroe Cap (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRCC#NASDAQ">MRCC</a>) is expected to report quarterly earnings at $0.27 per share on revenue of $14.99 million. 
• Longeveron (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGVN#NASDAQ">LGVN</a>) is projected to report quarterly loss at $0.36 per share on revenue of $660 thousand. 
• Middlesex Water (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSEX#NASDAQ">MSEX</a>) is likely to report quarterly earnings at $0.37 per share on revenue of $45.00 million. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AMRX

ANIP

APLS

BFLY

BTCM

CLMT

DCBO

DIBS

FLGT

FLNT

FUBO

GTLS

MRCC

MSEX

OXSQ

RPID

RXRX

WULF

Earnings Scheduled For February 28, 2025

Longeveron Announces WHO Approval Of Non-Proprietary Name Laromestrocel For Cellular Therapy Lomecel-B In Alzheimer's And HLHS Treatment

<a href="https://scr.zacks.com/files/News/2024/Zacks_SCR_Research_11132024_LGVN_Sorensen-pdf.pdf" title="https://scr.zacks.com/files/News/2024/Zacks_SCR_Research_11132024_LGVN_Sorensen-pdf.pdf">https://scr.zacks.com/files/News/2024/Zacks_SCR_Research_11132024_LGVN_Sorensen-pdf.pdf</a>

Watching Longeveron; Zacks Small-Cap Research Sets $9.50 Price Valuation

Longeveron (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGVN#NASDAQ">LGVN</a>) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.44) by 22.73 percent. This is a 87.81 percent increase over losses of $(2.79) per share from the same period last year. The company reported quarterly sales of $773.000 thousand which beat the analyst consensus estimate of $397.000 thousand by 94.71 percent. This is a 415.33 percent increase over sales of $150.000 thousand the same period last year.

Earnings Beats

Longeveron Q3 2024 GAAP EPS $(0.34) Beats $(0.44) Estimate, Sales $773.000K Beat $397.000K Estimate

ABOS

ABSI

ACNT

AENT

AGEN

AIOT

AIRG

ALTG

AMBC

AMPS

APEI

AREB

ARIS

ARMN

ATRA

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

Comments

Longeveron

Longeveron (LGVN) 옵션

No option chain data available. Please try again later

뉴스

파트너 / 기고자

벤징가 글로벌